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INTRODUCTION
Scar formation is the final result in wound healing and col-
lagen is one of the key factors in scar formation. A cutaneous
scar caused by excessive inflammation and immature colla-
gen has a distinctly different collagen pattern compared to
normal skin collagen. The pattern of collagen in a scar shows
densely packed fibers instead of the reticular pattern seen in
unwounded dermis. Scar remodeling occurs during months
to years. The extracellular matrix is dynamic and constantly
being remodeled, and can be conceptualized as the balance
between synthesis, deposition, and degradation (1). A scar
connects the space between damaged tissue but maximum
tensile strength reaches only 70% of unwounded skin (2).
Although a scar is an essential part of the natural wound heal-
ing process, its apparent results are cosmetically and some-
times even psychologically troublesome. 
A scar is an important issue to Asians because Asians have
darker and more sensitive skin (Fitzpatrick skin type III-V)
than Caucasians, resulting in more visible scar formation. To
lower the chances of a visible scar, a more delicate and refined
technique was applied to Asian patients in the operative aspect
but the results were found to be beyond our control.
Scarring is a necessary part of wound healing but scarless
wound healing can occur in fetal wounds with true tissue
regeneration. Previous studies have shown that scarless fetal
wound healing is dependent on both wound size and gesta-
tional age (3). In general, a wound created early in gestation
heals without scarring whereas a wound created after the tran-
sition period heals similarly to postnatal wounds with scar
formation (4, 5). In the fetal rat model, wound healing and
regeneration of the skin and its appendage occurs without the
increase of excessive immature collagen during early preg-
nancy or mid-term pregnancy (days 16.5-18.5). During that
time, inflammatory reactions are hardly observed (4).
Lorenz et al. (6) demonstrated that intrauterine environ-
ment was not absolutely necessary for scarless healing. Sci-
entists began to focus on intrinsic differences in response to
injury by adult and fetal cells. Subsequent work has focused
primarily on intercellular signaling through cytokines and
growth factors. In the early period of adult wound healing,
factors such as transforming growth factor (TGF)-b, platelet-
derived growth factor (PDGF), and epidermal growth factor
(EGF) are reported to be extensively involved (7-9). Special
attention was focused when a study by Pedal et al. (10) showed
that EGF was involved in scarless wound healing in which
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Effect of Recombinant Human Epidermal Growth Factor Against
Cutaneous Scar Formation in Murine Full-thickness Wound Healing 
A visible cutaneous scar develops from the excess formation of immature collagen
in response to an inflammatory reaction. This study examined the role of epidermal
growth factor (EGF) in the formation of cutaneous scars. Twenty Crl:CD-1 (ICR)
mice were used and 2 full-thickness skin wounds were made on the dorsum of each
mouse. One of the wounds was treated with recombinant human EGF by local appli-
cation and the other was treated with saline for control until complete healing was
achieved. The EGF-treated group’s wounds healed faster than the control group’s.
The width of the scar was smaller by 30% and the area was smaller by 26% in the
EGF-treated group. Inflammatory cell numbers were significantly lower in the EGF-
treated group. The expression of transforming growth factor (TGF)-b1 in the EGF-
treated group was increased. It was observed that the amount of collagen in the EGF-
treated group was larger than the control group. In the EGF-treated group, the visi-
ble external scars were less noticeable than that in the control group. These results
suggest that EGF can reduce cutaneous scars by suppressing inflammatory reac-
tions, decreasing expression of TGF-b1, and mediating the formation of collagen.
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increased expression of EGF in the early murine fetal period
was found and decreased EGF expression was noted during
the scar formation at late pregnancy. 
Satici et al. (11) studied the levels of EGF, TNF-a, and TGF-
b concentration according to the type of scar in trachoma cor-
neitis patients. They found that the concentration of EGF
was inversely proportional to the severity of the scar. Several
studies on the suppression of scar formation by different cyto-
kines or drugs have been reported, but we have not been able
to find a study showing the direct relationship of EGF to scar
formation during wound healing (12-14). To support our
hypothesis that EGF may reduce scar formation during the
healing process, we examined the effects of EGF on scar for-
mation through gross, histological, and immunohistologi-
cal evaluations. And we also assessed the visible scar using
scar assessment scale.
MATERIALS AND METHODS
Animal care
The Yonsei University Institutional Animal Care and Use
Committee approved all animal experiment protocols. All ani-
mals received care in compliance with the National Research
Council’s criteria as outlined in the ‘‘Guide for the Care of
Laboratory Animals’’ prepared by the Institute of Laborato-
ry Animal Resources and published by the National Insti-
tutes of Health.
Experimental design
Twenty Crl:CD-1 (ICR) mice were used in this experiment.
All animals were 6-8 weeks of age and weighed approximately
30-40 g. Intraperitoneal injections of 45 mg/kg of ketamine
(Ketara
�, Yoohan Medica Corporation, Seoul, Korea) and 3
mg/kg of xylazine (Rompun
�, Bayer HealthCare, Leverkusen,
Germany) were administrated for anesthesia. The dorsal hairs
were completely removed and sterilized with betadine and
alcohol. Using an 8-mm punch, full-thickness skin defect
wounds were created vertically in 2 areas. Subsequently, occlu-
sive dressings were performed with Tegaderm
� (3 M corpo-
rate, St. Paul, MN, USA). The following control and exper-
imental groups were designed; the experimental group had
distal wound treated using 0.2 mL (100 mg) of recombinant
human EGF (Easyef
�, 50 mg/100 mL ([60,000,000 IU],
Daewoong Pharmaceutical, Seoul, Korea) and the control
group had proximal wound treated using 0.2 mL of saline.
Both wound groups were treated daily until complete wound
closure.
Effect on wound closure; measurement of external would 
Digital images of the dorsal wounds were taken every 3 days
until complete wound closure (n=10). The external wound
area of both the experiment and control groups were measured
using Scion Image
�(NIH-Scion Corporation, Frederick, MD,
USA) software. The correlation of the time to complete wound
closure and to the time to half size of the initial wound (HT50:
healing time of 50% of the area) were obtained and compared
objectively.
Effect on scar formation; measurement of scar width and
cross-sectional scar area
Four weeks after the creation of the wounds, full-thickness
tissues biopsies were performed, including the scar and peri-
pheral normal skin (n=10). They were embedded in paraffin
and 5 mm sections were obtained and stained with hematoxylin
and eosin (H&E). After being stained with H&E, tissue sec-
tions at the central scar area were observed under a microscope
(BX-41, Olympus, Tokyo, Japan) at a fixed magnification
(×40), and the images were digitally recorded into a com-
puter by the OLYSIA
� (Olympus, Tokyo, Japan). The scar
width was determined by measuring the distance between
two wound edges located at the middle point between the
epidermis and the panniculus muscle. The relative area bet-
ween two wound edges beneath the epidermis and above the
panniculus muscle was also measured and recorded using same
slide. The measurements of both groups were compared and
statistically analyzed 
Effect on inflammatory reaction; inflammatory cell count
Three days after the creation of the wounds, full-thickness
skin biopsies were obtained (n=5) in the proximal, distal, and
left, right wound margins. The high power field (×400) un-
der the magnification by light microscope was divided into
4 areas and the number of inflammatory cells in each area
was counted and the mean and standard deviation of the EGF-
treated and control groups were calculated and statistically
compared. 
Effect on expression of TGF-b1; immunohistochemical
staining 
Four days after the creation of the wounds, immunohisto-
chemical staining for TGF-b1was performed (n=5). The biop-
sy tissues were embedded in paraffin block and it was section-
ed as 5 mm thickness. After rehydration, they were incubated
with the primary antibody monoclonal rat anti-mouse TGF-
b1 (TGF-b1(v):sc146: Santa Cruz Biotechnology, Santa Cruz,
CA, USA) diluted to 1:100 for 1 hr. The biopsy tissues were
subsequently incubated with secondary antibody tagging in
brown, treated with hematoxylin as counter-staining and exa-
mined under a light microscope. Effect on synthesis and organization of collagen; Masson’s
trichrome staining
Trichrome staining was performed to stain collagen fiber.
After rehydration and preheating of tissue slide, they were
incubated in Bouin’s solution for 15 min and cooled for 2 min.
The samples were stained with Weigert’s iron hematoxylin
solution for 5 min, washed, and stained with Beibrich scar-
let-acid fuchsin for 5 min. After 5 min incuation in phospho-
tungstic/phosphomolybdic acid solution, they were stained
with aniline blue solution. After incubated with 1% acetic
acid for 2 min, they were dehydrated and mounted. 
Statistical analysis 
Statistical analysis was performed using SPSS version 11 sta-
tistical software. Each measurement is shown as mean±stan-
dard deviation. All pairwise differences between the measure-
ments of two groups were examined by a paired t-test. A P
value of less than 0.05 was considered statistically significant.
RESULTS
Wound size and timing of closure
The initial wound measurement after using an 8-mm punch
(51 mm2) showed an area slightly larger (average, 71 mm2)
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Fig. 1. Time-wound area curve for degree of healing in each group
shows that full-thickness wounds heal more rapidly in the EGF-treat-
ed group than the control group. Healing time (HT50) was about 5.4
days in the EGF- treated group and 7.5 days in the control group.
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Fig. 2. Gross pictures of both wounds
were taken every 3 days after full-thick-
ness skin excision. Wound size decreas-
es more rapidly in the EGF-treated group. 
POD, Post-operative day.
Control
Initial POD #3 POD #9
EGF
POD #18
Fig. 3. Cross-sections of wounds stained with Masson’s trichrome staining. Scar width and area (above the panniculus muscle) are signif-
icantly reduced in 4 weeks postoperatively in the EGF-treated group compared to the control group (×40).
Control EGFcompared to that of the punch size. This is due to the region-
al skin contracture and the centrifugal force around the wound.
The wound healing rate showed a difference in time, partic-
ularly between the 3rd and 6th day. Reduction of the wound
area in the experimental group was much faster than the con-
trol group (Fig. 1). The average healing time of HT50 of the
EGF-treated group was 5.4 days and control group was 7.5
days. The EGF-treated group showed faster wound healing
than the control group (P<0.001) (Fig. 1). 
Maximal scar width and cross-sectional scar area
The scar width of the EGF-treated group was statistically
narrower with an average of 2.21±0.54 mm compared to
the control group of 3.18±0.57 mm. The EGF-treated group
had a smaller scar width than the control group by an approx-
imate average of 69.1%, which reveals that the EGF-treated
group contributed to the reduction of scar width by about
30%, and this is statistically significant (P=0.025) (Figs. 2,
3). The scar area of the EGF-treated group on average was
1.54±0.25 mm2and the control group was 2.08±0.34 mm2.
This showed that the cross-sectional scar area of the EGF-treat-
ed group was approximately 74% of the control group and
in the EGF-treated group, it contributed to the reduction of
the scar area by approximately 26% and was statistically sig-
nificant (P=0.022).
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Fig. 4. Counts of inflammatory cells. (A, B) Histopathological sections in control and EGF groups (H&E, ×100). (C) The graph shows the
effect of EGF on reducing inflammatory cells (cell counts/high power field [HPF], ×400).
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Fig. 5. Immunohistochemical observation of full-thickness wound at 4 days. The immunoactive area of TGF-b1 (brown) is markedly increased
in the control group, especially in the stroma (A, C). The expression of TGF-b1 was decreased in the EGF-treated group (B, E) but increased
in the adjacent normal skin area (D). 
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In the EGF-treated group, the number of inflammatory
cells was decreased noticeably. The results showed that the
mean value of the EGF-treated group was 32.6±8.8 cells
and the control group was 52.4±16.2 cells. This result was
also statistically significant (P=0.001) (Fig. 4).
TGF-b1 expression
In the EGF-treated group, TGF-b1 expression was relatively
decreased compared to the control group. The control group
showed increased brown secondary antibody, especially around
the stroma. This finding was in contrast to the normal tissues
in the vicinity of the wound where the pattern of expression
of TGF-b1 was not increased in both the EGF-treated and
control groups (Fig. 5). 
Collagen pattern 
In tissue samples examined after 4 weeks, the amount of
collagen in the EGF-treated group was higher than the con-
trol group. However, regarding its arrangement and amount,
it was not different from normal skin. In the control group,
the pattern of the formation of immature collagen was detect-
ed but not substantial (Fig. 6).
DISCUSSION
EGF has been known to be one of the important growth
factors in wound healing (9). It was discovered accidentally
during the separation of the neuronal growth factor from the
murine submandibular gland by Stanley Cohen in 1960 (15).
It has been reported to accelerate wound healing in the skin,
cornea, and gastric mucosa. EGF has been found to be simi-
lar to polypeptides such as TGF-a, heparin-binding EGF,
amphiregulin, epiregulin, and betacellulin. It is secreted from
platelets, keratinocytes, and macrophages that appear dur-
ing the wound healing process. EGF stimulates mitosis and
chemostasis of epithelial cells, consequently stimulating epi-
thelization (16, 17). In addition, EGF has been known to
influence wound healing by accelerating fibronectin synthe-
sis (18). Clinical application has been reported to support the
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Fig. 6. Trichrome staining for collagen pattern in each group at 3 weeks. In the EGF-treated group, the epidermis is well established. Col-
lagen bundles are mature, organized, and well arranged. The amount of collagen is similar to that of normal stroma. In contrast, an imma-
ture, disorganized collagen pattern is noted in the control group and the amount of collagen is smaller than that of normal stroma.
Control EGF
Wound
Control EGF
Adjacent skinmany roles of EGF accelerating wound healing, such as par-
tial-thickness wounds, or chronic wounds, such as diabetic
foot (19, 20).
Since 1983, recombinant human EGF (rh-EGF) has been
produced in large quantities by the recombination of the hu-
man EGF gene and expression in microorganisms. It has been
reported that rh-EGF stimulates cell proliferation and division
by binding to EGF receptors and activating tyrosine kinase
present in the cell membrane. Studies that examined growth
factors involved in scar formation used 16-day-old fetus mod-
els during murine pregnancy when scarring was absent. If
artificial wounds were formed on the fetus models prior to
16 days, a scar will not form because the distribution of growth
factors changed around 19 days. Dang et al. (2) have report-
ed that during this period, TGF-b1 was significantly reduced
compared to the scar formation period on the 19th day and
another growth factor, fibroblast growth factor (FGF-7, 10),
was also decreased. Peled et al. (10) have reported that dur-
ing the same period, TGF-b1 expression level was decreased
and EGF was simultaneously increased. Shah et al. (7) have
reported that scar formation could be suppressed by the sup-
pression of TGF-b1,2. 
In our study, to rule out the individual variation of mice,
equal-sized wounds were created on each mouse. Prior to the
objective evaluation of scar formation, basic wound healing
levels were evaluated to confirm that EGF accelerates wound
healing in various types of wounds. This was basically a recon-
firmation of previous reports on enhanced epithelial healing
of skin wounds of pigs and rats (9). We have also observed
acceleration of wound healing by the application of EGF to
chronic ulcerous wounds and the donor area of partial-thick-
ness skin. This is due to the reaction of EGF stimulating the
division of keratinocytes and fibroblasts, resulting in epithe-
lization. In addition, EGF has been shown to stimulate the
formation of collagen fibers and increase tension after skin
incision wounds in mice (1, 2). Our study revealed similar
findings in which EGF-treated groups achieved statistically
faster reductions in wound areas where the HT50 of the EGF-
treatment group was approximately 5.4 days compared to
7.5 days in the control group. Although, our study showed
the effect of EGF on wound healing & scar formation, one
limitation of the experimental design of this study should
be addressed regarding the application of EGF. To maintain
the effect of EGF continuously and mimic the physiology of
growth factors behind wound healing, EGF was applied daily.
However, the half life of recombinant EGF used in this study
is 2.4 hr (noticed by manufacturer). Therefore, to maintain the
effect of EGF during the wound healing process, EGF should
be used more than single application considering half life of
EGF. If that, the results of this study would be more distinct. 
We harvested the tissue samples 4 weeks after wounding
when they were completely healed to evaluate the scar width
and area and to assess the visible scar. In order to accurately
measure the width and area of the scars, it would have been
ideal to evaluate the wound after a longer period but such fol-
low-up observations could not be performed readily in mice
due to their short lifespan. Another limitation in the mouse
wound model is that visible scars do not last. Despite the limi-
tations, the amount of early formed scars was thought to be
significant enough at 4 weeks when the tissue samples were
obtained. The measurements of the scar width and area showed
that scars in the EGF-treated group were 69.1% of the con-
trol group’s in regard to the width and 74% of the control
group’s in regard to the area. From this observation, it was
possible to assume that EGF mediated an effect on the reduc-
tion of scar formation. It is without question that multiple
factors are involved in reducing scar width and area. Among
them is the role of EGF to enhance epithelialization but the
key factor behind contraction is caused by myofibroblasts.
It has been reported such myoblasts have been shown to be
influenced by growth factors from adjacent cells (21). Baek
et al. (22) confirmed the increase of myofibroblasts in the EGF-
treated group, and based on this, it can be said that EGF medi-
ates an effect on wound contractility through the stimulation
of myoblast proliferation. Therefore, it can be concluded that
EGF reduces scar width and area not only through rapid epi-
thelization but also by contracting the wound. 
One of the factors that also play a major role in scar forma-
tion is development of excessive inflammatory reaction dur-
ing the wound healing process in which fibrosis occurs in
abundance, leading to increased scar formation. In our study,
the distribution and number of inflammatory cells in the early
inflammatory reaction period in the EGF-treated group was
reduced in comparison with the control group. Babül et al.
(23) have reported that EGF was administered to artificial
wounds of mice, and the results showed that histamine con-
tents were decreased and the abnormal increase of collagen
could be suppressed. The number of inflammatory cells was
decreased in our study, which could be understood as the reduc-
tion of inflammatory reaction due to the decrease of inflam-
matory cytokines. 
In tissues examined on the 4th week, the EGF-treated group
demonstrated increased amount of collagen compared to the
control group but regarding the arrangement or the amount,
it was not statistically different from that of the normal skin
taken around the wound. The control group showed patterns
of immature collagen not seen from the groups treated with
EGF or the normal skin but the amount was not substantial.
Therefore, it can be reported that EGF stimulates collagen
production but produces mature collagen, and that the pro-
duction in quantity is similar as seen in normal skin. But to
further evaluate regarding collagen synthesis and remodeling,
the mouse model itself has limitations. The next step will be
to examine the effect in other animal models, such as pigs,
that have similar healing processes as humans.   
In immunohistochemical staining, the expression of TGF-
b1, which has been reported to mediate scar formation, was
found to be suppressed in the EGF-treated group. TGF-b is
594 Y.S. Kim, D.H. Lew, K.C. Tark, et al.an important growth factor in cell proliferation and division
as well as the control of extracellular matrix composition. It
has been reported to be released by activated T lymphocytes
and macrophages primarily. TGF-b has been reported to in-
duce fibrosis by accelerating fibroblast proliferation directly
and excess TGF-b1has been reported to be a causative of diverse
fibrosis diseases together with scar contracture (7). In our study,
the expression of TGF-b1 within wounds was lower in the
EGF-treated group. We further examined the skin around
the wound and found that the level of TGF-b1 was lower than
the wound in both groups. According to this result, we can
acknowledge that the EGF-treated group increased the syn-
thesis of collagen to a near-normal level and played a role in
obtaining maturity level without the influence of TGF-b1.  
In conclusion, the data in this study support the hypothe-
sis that EGF enhances not only wound healing through rapid
epithelialization but also plays a role in reducing scar forma-
tion in mice. The mechanism behind scar reduction can be
from fast epithelization, skin contraction, suppression of in-
flammatory reaction, mature collagen remodeling, and sup-
pression of TGF-b1. Although the data supports the positive
role of EGF against scar formation, further studies should be
needed to clarify whether EGF plays a role through regulat-
ing fibroblast, modifying epithelialization and decreased in-
flammatory reaction at the molecular level. And also, these
effects should be evaluated in human beings. 
ACKNOWLEDGEMENT
None of the authors have any conflict of interest in any of
the products, devices, or drugs mentioned in this article.
REFERENCES
1. Lorenz HP, Longaker MT. Wound healing: Repair biology and wound
and scar treatment. In: Mathes SJ, editor. Plastic surgery, 2nd ed,
vol 1. Philadelphia: Saunders 2006; 209-35.
2. Dang CM, Beanes SR, Soo C, Ting K, Benhaim P, Hedrick MH,
Lorenz HP. Decreased expression of fibroblast and keratinocyte
growth factor isoforms and receptors during scarless repair. Plast
Reconstr Surg 2003; 111: 1969-79.
3. Cass DL, Bullard KM, Sylvester KG, Yang EY, Longaker MT, Adz-
ick NS. Wound size and gestational age modulate scar formation in
fetal wound repair. J Pediatr Surg 1997; 32: 411-5.
4. Longaker MT, Whitby DJ, Adzick NS, Crombleholme TM, Langer
JC, Duncan BW, Bradley SM, Stern R, Ferguson MW, Harrison MR.
Studies in fetal wound healing: VI. Second and early third trimester
fetal wounds demonstrate rapid collagen deposition without scar for-
mation. J Pediatr Surg 1990; 25: 63-8.
5. Lorenz HP, Whitby DJ, Longaker MT, Adzick NS. Fetal wound
healing: The ontogeny of scar formation in the non-human primate.
Ann Surg 1993; 217: 391-6.
6. Lorenz HP, Longaker MT, Perkocha LA, Jennings RW, Harrison
MR, Adzick NS. Scarless wound repair: a human fetal skin model.
Development 1992; 114: 253-9.
7. Shah M, Foreman DM, Ferguson MW. Neutrolizing antibody to TGF-
beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;
107: 1137-57.
8. Hynes JH, Johnson DE, Mast BA, Diegelmann RF, Salzberg DA,
Cohen IK, Krummel TM. Platelet-derived growth factor induces
fetal wound fibrosis. J Pediatr Surg 1994; 29: 1405-8.
9. Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curt-
singer LJ 3rd, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. En-
hancement of wound healing by topical treatment with epidermal
growth factor. N Engl J Med 1989; 321: 76-9.
10. Peled ZM, Rhee SJ, Hsu M, Chang J, Krummel TM, Longaker MT.
The ontogeny of scarless healing II: EGF and PDGF-B gene expres-
sion in fetal rat skin and fibroblast as a function of gestational age.
Ann Plast Surg 2001; 47: 417-24.
11. Satici A, Guzey M, Dogan Z, Kilic A.Relationship between tear TNF-
alpha, TGF-beta1, and EGF levels and severity of cunjunctival cica-
trization in patients with inactive trachoma. Ophthalmic Res 2003;
35: 301-5.
12. Repertinger SK, Campagnaro E, Fuhrman J, El-Abaseri T, Yuspa
SH, Hansen LA. EGFR enhances early healing after cutaneous inci-
sional wounding. J Invest Dermatol 2004; 123: 982-9.
13. Wilgus TA, Vodovotz Y, Vittadini E, Clubbs EA, Oberyszyn TM.
Reduction of scar formation in full-thickness wounds with topical
celecoxib treatment. Wound Repair Regen 2003; 11: 25-34.
14. Liu W, Chua C, Wu X, Wand D, Ying D, Cui L, Cao Y. Inhibiting
scar formation in rat wounds by adenovirus-mediated overexpres-
sion of truncated TGF-beta receptor II. Plast Reconstr Surg 2005;
115: 860-70.
15. Cohen S. Isolation of a mouse submaxillary gland protein accelerat-
ing incisor eruption and eyelid opening in the new-born animal. J
Biol Chem 1962; 237: 1555-62.
16. Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth
factor and related growth factors in mammals. Endocr Rev 1990; 11:
418-42.
17. Bennett NT, Schultz GS. Growth factors and wound healing: bio-
chemical properties of growth factors and their receptors. Am J Surg
1993; 165: 728-37.
18. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Epi-
dermal growth factor induces fibronectin expression in human der-
mal fibroblasts via protein kinase C d signaling pathway. J Invest
Dermatol 2004; 122: 1390-8.
19. Brown GL, Curtsinger L 3rd, Brightwell JR, Ackerman DM, Tobin
GR, Polk HC Jr, George-Nascimento C, Valenzuela P, Schultz GS.
Enhancement of epidermal regeneration by biosynthetic epidermal
growth factor. J Exp Med 1986; 163: 1319-24.
20. Brown GL, Curtsinger L, Jurkiewicz MJ, Nahai F, Schultz G. Stim-
ulation of healing of chronic wounds by epidermal growth factor.
Plast Reconstr Surg 1991; 88: 189-94.
21. Liu M, Warn JD, Fan Q, Smith PG. Relationships between nerves
and myofibroblasts during cutaneous wound healing in the develop-
ing rat. Cell Tissue Res 1999; 297: 423-33.
Effect of Epidermal Growth Factor on Scar Formation 59522. Baek RM, Song YT, Baek SJ, Lee JH, Im TG, Yoon BH. Effects of
the recombinant human epidermal growth factor on full thickness
wound of the rat skin. J Korean Soc Plast Recontr Surg 2003; 30:
201-8.
23. Babu_l A, Gonul B, Dincer S, Erdogan D, Ozogul C. The effect of
EGF application in gel form on histamine content of experimentally
induced wound in mice. Amino Acids 2004; 27: 321-6.
596 Y.S. Kim, D.H. Lew, K.C. Tark, et al.